# US 2015/0105407 A1 · Substituted Pyrrolo, -Furano, and Cyclopentylpyrimidines Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105407 A1
- Document ID: US20150105407A1
- Status: Published application
- Kind: A1
- Application number: 14/573,427
- Filed: 2014-12-17
- Published: 2015-04-16
- Earliest claimed: 2008-07-10
- Assignees: Duquesne University of the Holy Spirit
- Applicants: Duquesne University of the Holy Spirit
- Inventors: Aleem Gangjee
- Web page: https://patentgrep.com/patent/US20150105407A1

## CPC

- C07D 491/048: the oxygen-containing ring being five-membered
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07D 239/70: condensed with carbocyclic rings or ring systems
- C07D 487/04: Ortho-condensed systems
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention provides substituted pyrrolo-, furano-, and cyclopentylpyrimidine bicyclic compounds of Formula III, and Formula IV, and pharmaceutically acceptable salts, solvates, and hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, such as for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds and pharmaceutical compositions for treating tumor cells and inhibiting mitosis of cancerous cells.

## Claims

### Claim 1

A compound comprising Formula III:
with respect to the five membered ring;
R1 and R2 may be the same or different and each is one of (a) a hydrogen (H), (b) an alkyl having from one to ten carbon atoms and having a straight or branched configuration, and wherein the alkyl is partially or completely saturated, or a substituted alkyl having from one to ten carbon atoms, (c) a cycloalkyl having from three to ten carbon atoms, or a substituted cycloalkyl having from three to ten carbon atoms, (d) an alkylcycloalkyl, or a substituted alkylcycloalkyl, (e) an aryl, or a substituted aryl, (f) an alkylaryl, or a substituted alkylaryl (g) a heteroaryl, or a substituted heteroaryl, (h) an alkylheteroaryl, or a substituted alkylheteroaryl, (i) an aromatic, or a substituted aromatic, and (j) a heteroaromatic, or a substituted heteroaromatic, and wherein each substituent of any said substituted group is the same or different and is selected from the group consisting of a straight or branched alkyl, alkenyl, or alkynyl, a cyclic or alicyclic group having from one to six carbon atoms, a heterocyclic group having from one to six carbon atoms, an alkoxy group, an aryloxy group, an alkyloxyaryloxy group, an aryl group, an amine, a halogen, a phenol, a naphthalene, a piperidine, a pyrrole, a ketone, a methylalkyl ketone, and a trifluoromethyl ketone, and wherein each of said substituents may itself be substituted, and wherein any of said substituents may be optionally attached by a CH2 bridge, and wherein the substituent may be optionally partially or completely saturated or unsaturated when it is not represented by said halogen;
wherein (i) and (j) may optionally be attached to Y via a CH2 bridge;
R3 is one of (a) a hydrogen (H), (b) a halogen, (c) an alkyl having from one to ten carbon atoms and having a straight or a branched configuration, and wherein the alkyl is partially or completely saturated; (d) an NH2, (e) an NHR7, (f) an NR7R8, (g) an OH, (h) an OR, (i) an SH, and (j) an SR, and wherein R is one of R1, and wherein R7 and R8 may be the same or different and each is one of R1;
R4 is one of (a) R1, (b) a halogen, (c) a mono-, di-, tri- or tetra-substituted alkyl, and (d) an alkyloxy, and wherein R1 is H or a lower alkyl and R2 is H or a lower alkyl then R4 is one of (a) a NR6R7, (b) a SR6, (c) a OR6, and (d) a CHR6R7, wherein R6 and R7 may be the same or different and each is one of R1 and R2;
R5 is one of R1;
R6 is one of R1;
X is one of (a) NR4, (b) an oxygen (O), and (c) R7CR4; and
Y is one of (a) a nitrogen (N), (b) an oxygen (O), (c) a sulfur (S), and (d) a CR6, wherein R6 is one of R1 and R3, and wherein when Y is O or S then R2 is absent or is zero.

### Claim 2 (depends on 1)

The compound of claim 1 wherein R5, R6, and R3 are the same moiety or wherein R7, R4, R6, and R5 are the same moiety.

### Claim 3 (depends on 2)

The compound of claim 2 wherein R7, R4, R6, and R5 are the same moiety of R1.

### Claim 4

A compound of Formula III:
with respect to the five membered ring;
R1 and R2 may be the same or different and each is one of (b) an alkyl having from one to ten carbon atoms and having a straight or branched configuration, and wherein the alkyl is partially or completely saturated, or a substituted alkyl having from one to ten carbon atoms, (c) a cycloalkyl having from three to ten carbon atoms, or a substituted cycloalkyl having from three to ten carbon atoms, (d) an alkylcycloalkyl, or a substituted alkylcycloalkyl, (e) an aryl, or a substituted aryl, (f) an alkylaryl, or a substituted alkylaryl (g) a heteroaryl, or a substituted heteroaryl, (h) an alkylheteroaryl, or a substituted alkylheteroaryl, (i) an aromatic, or a substituted aromatic, and (j) a heteroaromatic, or a substituted heteroaromatic, and wherein each substituent of any said substituted group is the same or different and is selected from the group consisting of a straight or branched alkyl, alkenyl, or alkynyl, a cyclic or alicyclic group having from one to six carbon atoms, a heterocyclic group having from one to six carbon atoms, an alkoxy group, an aryloxy group, an alkyloxyaryloxy group, an aryl group, an amine, a halogen, a phenol, a naphthalene, a piperidine, a pyrrole, a ketone, a methylalkyl ketone, and a trifluoromethyl ketone, and wherein each of said substituents may itself be substituted, and wherein any of said substituents may be optionally attached by a CH2 bridge, and wherein the substituent may be optionally partially or completely saturated or unsaturated when it is not represented by said halogen;
wherein (i) and (j) may optionally be attached to Y via a CH2 bridge;
wherein R1 and R2 are not each CH3;
R3 is one of (a) a hydrogen (H), (b) a halogen, (c) an alkyl having from one to ten carbon atoms and having a straight or a branched configuration, and wherein the alkyl is partially or completely saturated; (d) an NH2, (e) an NHR7, (f) an NR7R8, (g) an OH, (h) an OR, (i) an SH, and (j) an SR, and wherein R is one of R1, and wherein R7 and R8 may be the same or different and is one of R1;
R5 is one of (a) hydrogen (H) or (b) R1, except when R6 is a hydrogen (H), heteroaryl, or phenyl, wherein the phenyl and heteroaryl are optionally substituted with 1-2 moieties independently selected from the group consisting of halogen, (C1-C4)alkyl, (C1-C4)fluoroalkyl, (C1-C4)alkoxy, (C1-C4)alkylamine, and (C1-C4)dialkylamine, then R5 is not (i) a hydrogen (H), or (ii) a phenyl group substituted at any position with a substituent selected from the group consisting of (a) a hydrogen, (b) a halogen, (c) CN, (d) OH, (e) NH2, (f) (C1-C4)alkyl, (g) (C3-C6)cycloalkyl, (h) (C1-C4)fluoroalkyl, (i) (C1-C4)alkoxy, (j) (C1-C4)alkylamine, (k) (C1-C4)dialkylamine, (l) C(O)OH, (m) C(O)—NH2, (n) C(O)—(C1-C4)alkyl, (o) C(O)—(C1-C4)fluoroalkyl, (p) C(O)—(C1-C4)alkylamine, and (q) C(O)—(C1-C4)alkoxy;
R6 is one of (a) hydrogen (H) or (b) R1, and wherein R5 and R6 are not each a furan group;
X is an oxygen (O); and
Y is a nitrogen (N); and
wherein when Y is a nitrogen (N), and R3 is a hydrogen (H), and the bond 5-6 is a double bond, and R1 and R2 are independently selected from the group consisting of a substituted or unsubstituted alkyl, and a substituted or unsubstituted alkoxy, and R5 is selected from the group consisting of a hydrogen (H), an alkoxyalkyl, an alkyl, an optionally substituted arylalkyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkylalkyl, an optionally substituted heteroaralkyl, an optionally substituted (heterocycloalkyl)alkyl, and a halo, wherein the arylalkyl, the cycloalkyl, the cycloalkylalkyl, the heteroaralkyl, and the (heterocycloalkyl)alkyl are each optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkoxy, alkoxyalkyl, alkyl, cyano, halo, haloalkyl, hydroxy, hydroxyalkyl, and nitro, then R6 is not a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl wherein the heteroatom is a nitrogen (N).

### Claim 5

A pharmaceutical composition comprising a compound of Formula III and pharmaceutically acceptable salts, solvates, or hydrates thereof:
with respect to the five membered ring;
R1 and R2 may be the same or different and each is one of (a) a hydrogen (H), (b) an alkyl having from one to ten carbon atoms and having a straight or branched configuration, and wherein the alkyl is partially or completely saturated, or a substituted alkyl having from one to ten carbon atoms, (c) a cycloalkyl having from three to ten carbon atoms, or a substituted cycloalkyl having from three to ten carbon atoms, (d) an alkylcycloalkyl, or a substituted alkylcycloalkyl, (e) an aryl, or a substituted aryl, (f) an alkylaryl, or a substituted alkylaryl (g) a heteroaryl, or a substituted heteroaryl, (h) an alkylheteroaryl, or a substituted alkylheteroaryl, (i) an aromatic, or a substituted aromatic, and (j) a heteroaromatic, or a substituted heteroaromatic, and wherein each substituent of any said substituted group is the same or different and is selected from the group consisting of a straight or branched alkyl, alkenyl, or alkynyl, a cyclic or alicyclic group having from one to six carbon atoms, a heterocyclic group having from one to six carbon atoms, an alkoxy group, an aryloxy group, an alkyloxyaryloxy group, an aryl group, an amine, a halogen, a phenol, a naphthalene, a piperidine, a pyrrole, a ketone, a methylalkyl ketone, and a trifluoromethyl ketone, and wherein each of said substituents may itself be substituted, and wherein any of said substituents may be optionally attached by a CH2 bridge, and wherein the substituent may be optionally partially or completely saturated or unsaturated when it is not represented by said halogen;
wherein (i) and (j) may optionally be attached to Y via a CH2 bridge;
R3 is one of (a) a hydrogen (H), (b) a halogen, (c) an alkyl having from one to ten carbon atoms and having a straight or a branched configuration, and wherein the alkyl is partially or completely saturated; (d) an NH2, (e) an NHR7, (f) an NR7R8, (g) an OH, (h) an OR, (i) an SH, and (j) an SR, and wherein R is one of R1, and wherein R7 and R8 may be the same or different and each is one of R1;
R4 is one of (a) R1, (b) a halogen, (c) a mono-, di-, tri- or tetra-substituted alkyl, and (d) an alkyloxy, and wherein R1 is H or a lower alkyl and R2 is H or a lower alkyl then R4 is one of (a) a NR6R7, (b) a SR6, (c) a OR6, and (d) a CHR6R7, wherein R6 and R7 may be the same or different and each is one of R1 and R2;
R5 is one of R1;
R6 is one of R1;
X is one of (a) NR4, (b) an oxygen (O), and (c) R7CR4; and
Y is one of (a) a nitrogen (N), (b) an oxygen (O), (c) a sulfur (S), and (d) a CR6, wherein R6 is one of R1 and R3, and wherein when Y is O or S then R2 is absent or is zero.

### Claim 6

A pharmaceutical composition comprising a compound of Formula III and pharmaceutically acceptable salts, solvates, or hydrates thereof:
with respect to the five membered ring;
R1 and R2 may be the same or different and each is one of (b) an alkyl having from one to ten carbon atoms and having a straight or branched configuration, and wherein the alkyl is partially or completely saturated, or a substituted alkyl having from one to ten carbon atoms, (c) a cycloalkyl having from three to ten carbon atoms, or a substituted cycloalkyl having from three to ten carbon atoms, (d) an alkylcycloalkyl, or a substituted alkylcycloalkyl, (e) an aryl, or a substituted aryl, (f) an alkylaryl, or a substituted alkylaryl (g) a heteroaryl, or a substituted heteroaryl, (h) an alkylheteroaryl, or a substituted alkylheteroaryl, (i) an aromatic, or a substituted aromatic, and (j) a heteroaromatic, or a substituted heteroaromatic, and wherein each substituent of any said substituted group is the same or different and is selected from the group consisting of a straight or branched alkyl, alkenyl, or alkynyl, a cyclic or alicyclic group having from one to six carbon atoms, a heterocyclic group having from one to six carbon atoms, an alkoxy group, an aryloxy group, an alkyloxyaryloxy group, an aryl group, an amine, a halogen, a phenol, a naphthalene, a piperidine, a pyrrole, a ketone, a methylalkyl ketone, and a trifluoromethyl ketone, and wherein each of said substituents may itself be substituted, and wherein any of said substituents may be optionally attached by a CH2 bridge, and wherein the substituent may be optionally partially or completely saturated or unsaturated when it is not represented by said halogen;
wherein (i) and (j) may optionally be attached to Y via a CH2 bridge;
wherein R1 and R2 are not each CH3;
R3 is one of (a) a hydrogen (H), (b) a halogen, (c) an alkyl having from one to ten carbon atoms and having a straight or a branched configuration, and wherein the alkyl is partially or completely saturated; (d) an NH2, (e) an NHR7, (f) an NR7R8, (g) an OH, (h) an OR, (i) an SH, and (j) an SR, and wherein R is one of R1, and wherein R7 and R8 may be the same or different and is one of R1;
R5 is one of (a) hydrogen (H) or (b) R1, except when R6 is a hydrogen (H), heteroaryl, or phenyl, wherein the phenyl and heteroaryl are optionally substituted with 1-2 moieties independently selected from the group consisting of halogen, (C1-C4)alkyl, (C1-C4)fluoroalkyl, (C1-C4)alkoxy, (C1-C4)alkylamine, and (C1-C4)dialkylamine, then R5 is not (i) a hydrogen (H), or (ii) a phenyl group substituted at any position with a substituent selected from the group consisting of (a) a hydrogen, (b) a halogen, (c) CN, (d) OH, (e) NH2, (f) (C1-C4)alkyl, (g) (C3-C6)cycloalkyl, (h) (C1-C4)fluoroalkyl, (i) (C1-C4)alkoxy, (j) (C1-C4)alkylamine, (k) (C1-C4)dialkylamine, (l) C(O)OH, (m) C(O)—NH2, (n) C(O)—(C1-C4)alkyl, (o) C(O)—(C1-C4)fluoroalkyl, (p) C(O)—(C1-C4)alkylamine, and (q) C(O)—(C1-C4)alkoxy;
R6 is one of (a) hydrogen (H) or (b) R1, and wherein R5 and R6 are not each a furan group;
X is an oxygen (O); and
Y is a nitrogen (N); and
wherein when Y is a nitrogen (N), and R3 is a hydrogen (H), and the bond 5-6 is a double bond, and R1 and R2 are independently selected from the group consisting of a substituted or unsubstituted alkyl, and a substituted or unsubstituted alkoxy, and R5 is selected from the group consisting of a hydrogen (H), an alkoxyalkyl, an alkyl, an optionally substituted arylalkyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkylalkyl, an optionally substituted heteroaralkyl, an optionally substituted (heterocycloalkyl)alkyl, and a halo, wherein the arylalkyl, the cycloalkyl, the cycloalkylalkyl, the heteroaralkyl, and the (heterocycloalkyl)alkyl are each optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkoxy, alkoxyalkyl, alkyl, cyano, halo, haloalkyl, hydroxy, hydroxyalkyl, and nitro, then R6 is not a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl wherein the heteroatom is a nitrogen (N).

### Claim 7

A compound comprising Formula IV:
with respect to the five membered ring;
R1 and R2 may be the same or different and each is one of (a) a hydrogen (H), (b) an alkyl having from one to ten carbon atoms and having a straight or branched configuration, and wherein the alkyl is partially or completely saturated, or a substituted alkyl having from one to ten carbon atoms, (c) a cycloalkyl having from three to ten carbon atoms, or a substituted cycloalkyl having from three to ten carbon atoms, (d) an alkylcycloalkyl, or a substituted alkylcycloalkyl, (e) an aryl, or a substituted aryl, (f) an alkylaryl, or a substituted alkylaryl (g) a heteroaryl, or a substituted heteroaryl, (h) an alkylheteroaryl, or a substituted alkylheteroaryl, (i) an aromatic, or a substituted aromatic, and (j) a heteroaromatic, or a substituted heteroaromatic, and wherein each substituent of any said substituted group is the same or different and is selected from the group consisting of a straight or branched alkyl, alkenyl, or alkynyl, a cyclic or alicyclic group having from one to six carbon atoms, a heterocyclic group having from one to six carbon atoms, an alkoxy group, an aryloxy group, an alkyloxyaryloxy group, an aryl group, an amine, a halogen, a phenol, a naphthalene, a piperidine, a pyrrole, a ketone, a methylalkyl ketone, and a trifluoromethyl ketone, and wherein each of said substituents may itself be substituted, and wherein any of said substituents may be optionally attached by a CH2 bridge, and wherein the substituent may be optionally partially or completely saturated or unsaturated when it is not represented by said halogen;
wherein (i) and (j) may optionally be attached to Y via a CH2 bridge;
R3 is one of (a) a hydrogen (H), (b) a halogen, (c) an alkyl having from one to ten carbon atoms and having a straight or a branched configuration, and wherein the alkyl is partially or completely saturated; (d) an NH2, (e) an NHR7, (f) an NR7R8, (g) an OH, (h) an OR, (i) an SH, and (j) an SR, and wherein R is one of R1, and wherein R7 and R8 may be the same or different and each is one of R1;
R4 is one of (a) R1, (b) a halogen, (c) a mono-, di-, tri- or tetra-substituted alkyl, and (d) an alkyloxy, and wherein R1 is H or a lower alkyl and R2 is H or a lower alkyl then R4 is one of (a) a NR6R7, (b) a SR6, (c) a OR6, and (d) a CHR6R7, wherein R6 and R7 may be the same or different and each is one of R1 and R2;
R5 is one of R1;
R6 is one of R1;
X is one of (a) a NR4, (b) an oxygen (O), and (c) R7CR4; and
Y is one of (a) a nitrogen (N), (b) an oxygen (O), (c) a sulfur (S), and (d) a CR6, wherein R6 is one of R1 and R3, and wherein when Y is O or S then R2 is absent or is zero.

### Claim 8 (depends on 7)

The compound of claim 7 wherein R6 and R5 are the same moiety or wherein R5, R6, and R3 are the same moiety.

### Claim 9 (depends on 7)

The compound of claim 7 wherein R1 is a substituted aryl, R2 is CH3, R3 is CH3, X is NR4, R5 is H, and R6 is an alkylaryl group.

### Claim 10 (depends on 9)

The compound of claim 9 wherein R1 is a methoxyphenyl group, R2 is CH3, R3 is CH3, X is NR4 wherein R4 is H, R5 is H, R6 is an alkyl aryl group wherein the alkyl is —CH2— and the aryl is a phenyl group, and the bond 6, 7 is a double bond.

### Claim 11

A pharmaceutical composition comprising a compound of Formula IV and pharmaceutically acceptable salts, solvates, or hydrates thereof:
with respect to the five membered ring;
R1 and R2 may be the same or different and each is one of (a) a hydrogen (H), (b) an alkyl having from one to ten carbon atoms and having a straight or branched configuration, and wherein the alkyl is partially or completely saturated, or a substituted alkyl having from one to ten carbon atoms, (c) a cycloalkyl having from three to ten carbon atoms, or a substituted cycloalkyl having from three to ten carbon atoms, (d) an alkylcycloalkyl, or a substituted alkylcycloalkyl, (e) an aryl, or a substituted aryl, (f) an alkylaryl, or a substituted alkylaryl (g) a heteroaryl, or a substituted heteroaryl, (h) an alkylheteroaryl, or a substituted alkylheteroaryl, (i) an aromatic, or a substituted aromatic, and (j) a heteroaromatic, or a substituted heteroaromatic, and wherein each substituent of any said substituted group is the same or different and is selected from the group consisting of a straight or branched alkyl, alkenyl, or alkynyl, a cyclic or alicyclic group having from one to six carbon atoms, a heterocyclic group having from one to six carbon atoms, an alkoxy group, an aryloxy group, an alkyloxyaryloxy group, an aryl group, an amine, a halogen, a phenol, a naphthalene, a piperidine, a pyrrole, a ketone, a methylalkyl ketone, and a trifluoromethyl ketone, and wherein each of said substituents may itself be substituted, and wherein any of said substituents may be optionally attached by a CH2 bridge, and wherein the substituent may be optionally partially or completely saturated or unsaturated when it is not represented by said halogen;
wherein (i) and (j) may optionally be attached to Y via a CH2 bridge;
R3 is one of (a) a hydrogen (H), (b) a halogen, (c) an alkyl having from one to ten carbon atoms and having a straight or a branched configuration, and wherein the alkyl is partially or completely saturated; (d) an NH2, (e) an NHR7, (f) an NR7R8, (g) an OH, (h) an OR, (i) an SH, and (j) an SR, and wherein R is one of R1, and wherein R7 and R8 may be the same or different and each is one of R1;
R4 is one of (a) R1, (b) a halogen, (c) a mono-, di-, tri- or tetra-substituted alkyl, and (d) an alkyloxy, and wherein R1 is H or a lower alkyl and R2 is H or a lower alkyl then R4 is one of (a) a NR6R7, (b) a SR6, (c) a OR6, and (d) a CHR6R7, wherein R6 and R7 may be the same or different and each is one of R1 and R2;
R5 is one of R1;
R6 is one of R1;
X is one of (a) a NR4, (b) an oxygen (O), and (c) R7CR4; and
Y is one of (a) a nitrogen (N), (b) an oxygen (O), (c) a sulfur (S), and (d) a CR6, wherein R6 is one of R1 and R3, and wherein when Y is O or S then R2 is absent or is zero.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11 wherein R1 is a methoxyphenyl group, R2 is CH3, R3 is CH3, X is NR4 wherein R4 is H, R5 is H, R6 is an alkyl aryl group wherein the alkyl is —CH2— and the aryl is a phenyl group, and the bond 6, 7 is a double bond.

### Claim 13

A method of treating a patient diagnosed with cancer comprising administering to the patient a therapeutically effective amount of a compound of Formula III:
with respect to the five membered ring;
R1 and R2 may be the same or different and each is one of (a) a hydrogen (H), (b) an alkyl having from one to ten carbon atoms and having a straight or branched configuration, and wherein the alkyl is partially or completely saturated, or a substituted alkyl having from one to ten carbon atoms, (c) a cycloalkyl having from three to ten carbon atoms, or a substituted cycloalkyl having from three to ten carbon atoms, (d) an alkylcycloalkyl, or a substituted alkylcycloalkyl, (e) an aryl, or a substituted aryl, (f) an alkylaryl, or a substituted alkylaryl (g) a heteroaryl, or a substituted heteroaryl, (h) an alkylheteroaryl, or a substituted alkylheteroaryl, (i) an aromatic, or a substituted aromatic, and (j) a heteroaromatic, or a substituted heteroaromatic, and wherein each substituent of any said substituted group is the same or different and is selected from the group consisting of a straight or branched alkyl, alkenyl, or alkynyl, a cyclic or alicyclic group having from one to six carbon atoms, a heterocyclic group having from one to six carbon atoms, an alkoxy group, an aryloxy group, an alkyloxyaryloxy group, an aryl group, an amine, a halogen, a phenol, a naphthalene, a piperidine, a pyrrole, a ketone, a methylalkyl ketone, and a trifluoromethyl ketone, and wherein each of said substituents may itself be substituted, and wherein any of said substituents may be optionally attached by a CH2 bridge, and wherein the substituent may be optionally partially or completely saturated or unsaturated when it is not represented by said halogen;
wherein (i) and (j) may optionally be attached to Y via a CH2 bridge;
R3 is one of (a) a hydrogen (H), (b) a halogen, (c) an alkyl having from one to ten carbon atoms and having a straight or a branched configuration, and wherein the alkyl is partially or completely saturated; (d) an NH2, (e) an NHR7, (f) an NR7R8, (g) an OH, (h) an OR, (i) an SH, and (j) an SR, and wherein R is one of R1, and wherein R7 and R8 may be the same or different and is one of R1;
R4 is one of (a) R1, (b) a halogen, (c) a mono-, di-, tri- or tetra-substituted alkyl, and (d) an alkyloxy, and wherein R1 is H or a lower alkyl and R2 is H or a lower alkyl then R4 is one of (a) a NR6R7, (b) a SR6, (c) a OR6, and (d) a CHR6R7, wherein R6 and R7 may be the same or different and is one of R1 and R2;
R5 is one of R1;
R6 is one of R1;
X is one of (a) NR4, (b) an oxygen (O), and (c) R7CR4; and
Y is one of (a) a nitrogen (N), (b) an oxygen (O), (c) a sulfur (S), and (d) a CR6, wherein R6 is one of R1 and R3, and wherein when Y is O or S then R2 is absent or is zero, for achieving a therapeutic response.

### Claim 14 (depends on 13)

The method of claim 13 including administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising a compound of Formula III and pharmaceutically acceptable salts, solvates, or hydrates thereof.

### Claim 15

A method of treating a patient diagnosed with cancer comprising administering to the patient a therapeutically effective amount of a compound of Formula IV:
with respect to the five membered ring;
R1 and R2 may be the same or different and each is one of (a) a hydrogen (H), (b) an alkyl having from one to ten carbon atoms and having a straight or branched configuration, and wherein the alkyl is partially or completely saturated, or a substituted alkyl having from one to ten carbon atoms, (c) a cycloalkyl having from three to ten carbon atoms, or a substituted cycloalkyl having from three to ten carbon atoms, (d) an alkylcycloalkyl, or a substituted alkylcycloalkyl, (e) an aryl, or a substituted aryl, (f) an alkylaryl, or a substituted alkylaryl (g) a heteroaryl, or a substituted heteroaryl, (h) an alkylheteroaryl, or a substituted alkylheteroaryl, (i) an aromatic, or a substituted aromatic, and (j) a heteroaromatic, or a substituted heteroaromatic, and wherein each substituent of any said substituted group is the same or different and is selected from the group consisting of a straight or branched alkyl, alkenyl, or alkynyl, a cyclic or alicyclic group having from one to six carbon atoms, a heterocyclic group having from one to six carbon atoms, an alkoxy group, an aryloxy group, an alkyloxyaryloxy group, an aryl group, an amine, a halogen, a phenol, a naphthalene, a piperidine, a pyrrole, a ketone, a methylalkyl ketone, and a trifluoromethyl ketone, and wherein each of said substituents may itself be substituted, and wherein any of said substituents may be optionally attached by a CH2 bridge, and wherein the substituent may be optionally partially or completely saturated or unsaturated when it is not represented by said halogen;
wherein (i) and (j) may optionally be attached to Y via a CH2 bridge;
R3 is one of (a) a hydrogen (H), (b) a halogen, (c) an alkyl having from one to ten carbon atoms and having a straight or a branched configuration, and wherein the alkyl is partially or completely saturated; (d) an NH2, (e) an NHR7, (f) an NR7R8, (g) an OH, (h) an OR, (i) an SH, and (j) an SR, and wherein R is one of R1, and wherein R7 and R8 may be the same or different and each is one of R1;
R4 is one of (a) R1, (b) a halogen, (c) a mono-, di-, tri- or tetra-substituted alkyl, and (d) an alkyloxy, and wherein R1 is H or a lower alkyl and R2 is H or a lower alkyl then R4 is one of (a) a NR6R7, (b) a SR6, (c) a OR6, and (d) a CHR6R7, wherein R6 and R7 may be the same or different and is one of R1 and R2;
R5 is one of R1;
R6 is one of R1;
X is one of (a) a NR4, (b) an oxygen (O), and (c) R7CR4; and
Y is one of (a) a nitrogen (N), (b) an oxygen (O), (c) a sulfur (S), and (d) a CR6, wherein R6 is one of R1 and R3, and wherein when Y is O or S then R2 is absent or is zero, for achieving a therapeutic response.

### Claim 16 (depends on 15)

The method of claim 15 including administering to the patient a pharmaceutical composition comprising a compound of Formula IV and pharmaceutically acceptable salts, solvates, or hydrates thereof.

### Claim 17

A method for inhibiting the mitosis of one or more cancerous cells comprising subjecting one or more live cancerous cells to a mitotic inhibitory acceptable amount of a compound of Formula III, or a pharmaceutical composition comprising a compound of Formula III and pharmaceutically acceptable salts, solvates, or hydrates thereof:
with respect to the five membered ring;
R1 and R2 may be the same or different and each is one of (a) a hydrogen (H), (b) an alkyl having from one to ten carbon atoms and having a straight or branched configuration, and wherein the alkyl is partially or completely saturated, or a substituted alkyl having from one to ten carbon atoms, (c) a cycloalkyl having from three to ten carbon atoms, or a substituted cycloalkyl having from three to ten carbon atoms, (d) an alkylcycloalkyl, or a substituted alkylcycloalkyl, (e) an aryl, or a substituted aryl, (f) an alkylaryl, or a substituted alkylaryl (g) a heteroaryl, or a substituted heteroaryl, (h) an alkylheteroaryl, or a substituted alkylheteroaryl, (i) an aromatic, or a substituted aromatic, and (j) a heteroaromatic, or a substituted heteroaromatic, and wherein each substituent of any said substituted group is the same or different and is selected from the group consisting of a straight or branched alkyl, alkenyl, or alkynyl, a cyclic or alicyclic group having from one to six carbon atoms, a heterocyclic group having from one to six carbon atoms, an alkoxy group, an aryloxy group, an alkyloxyaryloxy group, an aryl group, an amine, a halogen, a phenol, a naphthalene, a piperidine, a pyrrole, a ketone, a methylalkyl ketone, and a trifluoromethyl ketone, and wherein each of said substituents may itself be substituted, and wherein any of said substituents may be optionally attached by a CH2 bridge, and wherein the substituent may be optionally partially or completely saturated or unsaturated when it is not represented by said halogen;
wherein (i) and (j) may optionally be attached to Y via a CH2 bridge;
R3 is one of (a) a hydrogen (H), (b) a halogen, (c) an alkyl having from one to ten carbon atoms and having a straight or a branched configuration, and wherein the alkyl is partially or completely saturated; (d) an NH2, (e) an NHR7, (f) an NR7R8, (g) an OH, (h) an OR, (i) an SH, and (j) an SR, and wherein R is one of R1, and wherein R7 and R8 may be the same or different and is one of R1;
R4 is one of (a) R1, (b) a halogen, (c) a mono-, di-, tri- or tetra-substituted alkyl, and (d) an alkyloxy, and wherein R1 is H or a lower alkyl and R2 is H or a lower alkyl then R4 is one of (a) a NR6R7, (b) a SR6, (c) a OR6, and (d) a CHR6R7, wherein R6 and R7 may be the same or different and each is one of R1 and R2;
R5 is one of R1;
R6 is one of R1;
X is one of (a) NR4, (b) an oxygen (O), and (c) R7CR4; and
Y is one of (a) a nitrogen (N), (b) an oxygen (O), (c) a sulfur (S), and (d) a CR6, wherein R6 is one of R1 and R3, and wherein when Y is O or S then R2 is absent or is zero, for achieving inhibition of mitosis of said cancerous cell(s).

### Claim 18

A method for inhibiting the mitosis of one or more cancerous cells comprising subjecting one or more live cancerous cells to a mitotic inhibitory amount of a compound of Formula IV, or a pharmaceutical composition comprising a compound of Formula IV and pharmaceutically acceptable salts, solvates, or hydrates thereof:
with respect to the five membered ring;
R1 and R2 may be the same or different and each is one of (a) a hydrogen (H), (b) an alkyl having from one to ten carbon atoms and having a straight or branched configuration, and wherein the alkyl is partially or completely saturated, or a substituted alkyl having from one to ten carbon atoms, (c) a cycloalkyl having from three to ten carbon atoms, or a substituted cycloalkyl having from three to ten carbon atoms, (d) an alkylcycloalkyl, or a substituted alkylcycloalkyl, (e) an aryl, or a substituted aryl, (f) an alkylaryl, or a substituted alkylaryl (g) a heteroaryl, or a substituted heteroaryl, (h) an alkylheteroaryl, or a substituted alkylheteroaryl, (i) an aromatic, or a substituted aromatic, and (j) a heteroaromatic, or a substituted heteroaromatic, and wherein each substituent of any said substituted group is the same or different and is selected from the group consisting of a straight or branched alkyl, alkenyl, or alkynyl, a cyclic or alicyclic group having from one to six carbon atoms, a heterocyclic group having from one to six carbon atoms, an alkoxy group, an aryloxy group, an alkyloxyaryloxy group, an aryl group, an amine, a halogen, a phenol, a naphthalene, a piperidine, a pyrrole, a ketone, a methylalkyl ketone, and a trifluoromethyl ketone, and wherein each of said substituents may itself be substituted, and wherein any of said substituents may be optionally attached by a CH2 bridge, and wherein the substituent may be optionally partially or completely saturated or unsaturated when it is not represented by said halogen;
wherein (i) and (j) may optionally be attached to Y via a CH2 bridge;
R3 is one of (a) a hydrogen (H), (b) a halogen, (c) an alkyl having from one to ten carbon atoms and having a straight or a branched configuration, and wherein the alkyl is partially or completely saturated; (d) an NH2, (e) an NHR7, (f) an NR7R8, (g) an OH, (h) an OR, (i) an SH, and (j) an SR, and wherein R is one of R1, and wherein R7 and R8 may be the same or different and each is one of R1;
R4 is one of (a) R1, (b) a halogen, (c) a mono-, di-, tri- or tetra-substituted alkyl, and (d) an alkyloxy, and wherein R1 is H or a lower alkyl and R2 is H or a lower alkyl then R4 is one of (a) a NR6R7, (b) a SR6, (c) a OR6, and (d) a CHR6R7, wherein R6 and R7 may be the same or different and each is one of R1 and R2;
R5 is one of R1;
R6 is one of R1;
X is one of (a) a NR4, (b) an oxygen (O), and (c) R7CR4; and
Y is one of (a) a nitrogen (N), (b) an oxygen (O), (c) a sulfur (S), and (d) a CR6, wherein R6 is one of R1 and R3, and wherein when Y is O or S then R2 is absent or is zero, for achieving inhibition of mitosis of said cancerous cell(s).
